{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:43:30Z","timestamp":1776303810488,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005653","name":"Congress of Neurological Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11060-025-05074-1","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:44:52Z","timestamp":1753343092000},"page":"21-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update"],"prefix":"10.1007","volume":"175","author":[{"given":"Simon S.","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia M.","family":"Halasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony J. C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Kuo","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"3","key":"5074_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11060-015-1948-1","volume":"125","author":"TC Ryken","year":"2015","unstructured":"Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ (2015) The role of radiotherapy in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol Rev 125(3):551\u2013583. https:\/\/doi.org\/10.1007\/s11060-015-1948-1","journal-title":"J Neuro-Oncol Rev"},{"issue":"4","key":"5074_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.23736\/S0390-5616.19.04701-5","volume":"63","author":"RA Morshed","year":"2019","unstructured":"Morshed RA, Young JS, Hervey-Jumper SL, Berger MS (2019) The management of low-grade gliomas in adults. J Neurosurg Sci Rev 63(4):450\u2013457. https:\/\/doi.org\/10.23736\/S0390-5616.19.04701-5","journal-title":"J Neurosurg Sci Rev"},{"issue":"7","key":"5074_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/neuonc\/noz033","volume":"21","author":"D Schiff","year":"2019","unstructured":"Schiff D et al (2019) Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro Oncol 21(7):837\u2013853. https:\/\/doi.org\/10.1093\/neuonc\/noz033","journal-title":"Neuro Oncol"},{"issue":"6","key":"5074_CR4","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol Rev 18(6):e315\u2013e329. https:\/\/doi.org\/10.1016\/S1470-2045(17)30194-8","journal-title":"Lancet Oncol Rev"},{"key":"5074_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-019-0802-8","author":"MD Wood","year":"2019","unstructured":"Wood MD, Halfpenny AM, Moore SR (2019) Applications of molecular neuro-oncology\u2014a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol. https:\/\/doi.org\/10.1186\/s13000-019-0802-8","journal-title":"Diagn Pathol"},{"key":"5074_CR6","unstructured":"G. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice, in Clinical Practice Guidelines We Can Trust, R. Graham, M. Mancher, D. Miller Wolman, S. Greenfield, and E. Steinberg Eds. Washington (DC): National Academies Press (US) Copyright 2011 by the National Academy of Sciences. All rights reserved. (2011)."},{"issue":"6","key":"5074_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"8","key":"5074_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5074_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2137-6","author":"M Ziu","year":"2016","unstructured":"Ziu M, Olson JJ (2016) Update on the evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: the role of initial chemotherapy. J Neuro-Oncol. https:\/\/doi.org\/10.1007\/s11060-016-2137-6","journal-title":"J Neuro-Oncol"},{"key":"5074_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"10","key":"5074_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/cncr.29237","volume":"121","author":"HA Shih","year":"2015","unstructured":"Shih HA et al (2015) Proton therapy for low-grade gliomas: results from a prospective trial. Cancer 121(10):1712\u20131719. https:\/\/doi.org\/10.1002\/cncr.29237","journal-title":"Cancer"},{"issue":"1","key":"5074_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-015-1952-5","volume":"126","author":"JC Sherman","year":"2016","unstructured":"Sherman JC et al (2016) Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neuro-Oncol 126(1):157\u2013164. https:\/\/doi.org\/10.1007\/s11060-015-1952-5","journal-title":"J Neuro-Oncol"},{"key":"5074_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.04.027","volume":"137","author":"S Tabrizi","year":"2019","unstructured":"Tabrizi S et al (2019) Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol 137:95\u2013101. https:\/\/doi.org\/10.1016\/j.radonc.2019.04.027","journal-title":"Radiother Oncol"},{"issue":"1","key":"5074_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-018-03063-1","volume":"142","author":"M Dworkin","year":"2019","unstructured":"Dworkin M et al (2019) Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neuro-Oncol 142(1):69\u201377. https:\/\/doi.org\/10.1007\/s11060-018-03063-1","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"5074_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11060-013-1224-1","volume":"115","author":"F Ducray","year":"2013","unstructured":"Ducray F et al (2013) Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy. J Neurooncol 115(2):261\u2013265. https:\/\/doi.org\/10.1007\/s11060-013-1224-1","journal-title":"J Neurooncol"},{"issue":"2","key":"5074_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11060-017-2570-1","volume":"135","author":"O Etxaniz","year":"2017","unstructured":"Etxaniz O et al (2017) IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. J Neurooncol 135(2):273\u2013284. https:\/\/doi.org\/10.1007\/s11060-017-2570-1","journal-title":"J Neurooncol"},{"issue":"10","key":"5074_CR17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaoncol.2018.1977","volume":"4","author":"EH Bell","year":"2018","unstructured":"Bell EH et al (2018) Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology\/RTOG 0424 trial. JAMA Oncol 4(10):1405\u20131409. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1977","journal-title":"JAMA Oncol"},{"issue":"29","key":"5074_CR18","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/jco.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH et al (2020) Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38(29):3407\u20133417. https:\/\/doi.org\/10.1200\/jco.19.02983","journal-title":"J Clin Oncol"},{"key":"5074_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.11.027","author":"EM Hudson","year":"2024","unstructured":"Hudson EM et al (2024) Hitting the target: developing high-quality evidence for proton beam therapy through randomised controlled trials. Clin Oncol. https:\/\/doi.org\/10.1016\/j.clon.2023.11.027","journal-title":"Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05074-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T16:30:51Z","timestamp":1755707451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05074-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05074-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Guideline Task Force members were required to disclose all potential COIs prior to beginning work on the guideline, using the COI disclosure form of the AANS\/CNS Joint Guidelines Review Committee. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination and participation on the task force. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of task force members with possible conflicts and restrict the writing, reviewing, and\/or voting privileges of that person to topics that are unrelated to the possible COIs. The task force has not made any disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}